Association of body mass index and prostate cancer mortality - Abstract

OBJECTIVES: Inconsistent evidence exists on whether obesity is associated with an increased risk of prostate cancer death post-radical prostatectomy.

We examined data from three large health plans to evaluate if an increased body mass index (BMI) at prostate cancer diagnosis is related to prostate cancer mortality

SUBJECTS AND METHODS: This population-based case-control study included 751 men with prostate cancer who underwent radical prostatectomy. Cases were men who died due to prostate cancer (N=323) and matched controls (N=428). We used multivariable logistic regression models to assess the association between BMI at diagnosis and prostate cancer mortality, adjusted for Gleason score, PSA, tumour characteristics, and matching factors.

RESULTS: Study subjects were classified into the following BMI (kg/m(2)) categories: healthy (18.5-24.9), overweight (25-29.9) and obese (≥30). Nearly 43% of the participants had a BMI ≥25 at diagnosis. A higher fraction of cases (30%) were obese compared to controls (22%). Overall, obese men had more than a 50% increase in prostate cancer mortality (adjusted odds ratio=1.50 (95% CI, 1.03-2.19)) when compared to men with healthy BMI. After stratifying by Gleason score, the odds of mortality generally rose with increasing BMI. The strongest effect was observed in the Gleason score 8+ category (2.37, 95% CI: 1.11-5.09). These associations persisted after adjusting for PSA at diagnosis and other tumour characteristics.

CONCLUSIONS: These results suggest that BMI at diagnosis is strongly correlated with prostate cancer mortality, and that men with aggressive disease have a markedly greater odds of death if they are overweight or obese.

Written by:
Haque R, Van Den Eeden SK, Wallner LP, Richert-Boe K, Kallakury B, Wang R, Weinmann S.   Are you the author?
Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States; Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States; Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States; Georgetown University, Department of Pathology, Washington, DC, United States.  

Reference: Obes Res Clin Pract. 2014 Jul-Aug;8(4):e374-81.
doi: 10.1016/j.orcp.2013.06.002

PubMed Abstract
PMID: 25091359 Prostate Cancer Section







Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.